Critical

Fifth Circuit Stay Reinstates Nationwide In-Person Dispensing Requirement for Mifepristone - Reed Smith LLP

Detected July 28, 2026 · in Pharmacy & Controlled Substances

The Fifth Circuit reinstated the in-person dispensing requirement for mifepristone, reversing a prior ruling that allowed telehealth prescribing and mail-order dispensing. This change affects all pharmacies dispensing mifepristone, requiring immediate compliance with the original FDA Risk Evaluation and Mitigation Strategy (REMS) mandates.

Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Critical. All pharmacies dispensing mifepristone, including independent pharmacies, retail chains, compounding pharmacies, and long-term-care pharmacies. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon the stay's issuance (no grace period).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

The in-person dispensing requirement for mifepristone is reinstated nationwide. Telehealth prescribing and mail-order dispensing are no longer permitted unless the patient has an in-person visit with the prescriber and the medication is dispensed in person at a certified healthcare setting.

Who it affects

All pharmacies dispensing mifepristone, including independent pharmacies, retail chains, compounding pharmacies, and long-term-care pharmacies.

What you must do

Immediately cease any telehealth-only prescribing or mail-order dispensing of mifepristone. Ensure all dispensing occurs in person at a clinic, medical office, or hospital certified under the REMS program.

Deadline

Immediately upon the stay's issuance (no grace period).

Source: https://news.google.com/rss/articles/CBMi_AFBVV95cUxNTUxQRURVS3N6elJfX0hQTnFqV2szNEZrdWxCQXBDWjhJT1ROSHVGUU9IT2VWYUJzS3FfNDJlaW1Fb2NfNWI1Umk5V2tadmFtaHZkRC04VDJ0VFU4NVdacVRsV2JwUlh1a3puakZIbXI0c3ZsN3NiNmMzNjZ4ZGVSUHpQb2pPZ0VPZlNwMEQ1UGE1QzkxREhjUWlsN3RaTEVLTEdRX21nQmdpVFFVbnVzN0s5S051X1VwMTNFOEFDSVlFZWZGaldEdFpKYWZmd0V2ZXdBYXlZb055d2RvMDJMNTZsR19MbDhybU5sdXpJRXZEcjZNbzk0WHVzaUo?oc=5

Never miss a change like this again

Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmacy & Controlled Substances